ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.

Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the large-scale SOUL trial, which investigated the impact of oral semaglutide on type 2 diabetes patients with prior cardiovascular or chronic kidney disease. Patients were randomized 1:1 to recieve either a daily oral semaglutide tablet (3mg/7mg/14mg titration) or an oral placebo tablet. The primary outcome was time to first occurence of MACE, whilst secondary outcomes included a composite of renal outcomes, major adverse limb outcomes, heart failure outcomes, all-cause mortality, changes in HbA1c and body weight, and hypoglycemia episodes.

Findings showed that oral semaglutide had proven cardiovascular benefits, with consistent cardiovascular efficacy across subgroups by sex, age, BMI, eGFR and concomitant medication.

Recorded onsite at ACC 2025, Chicago.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Dan Brent, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe CVRM.